XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Operating Activities:    
Net loss $ (93,113) $ (78,939)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation and amortization 4,120 2,639
Amortization of premium (discount) on marketable securities 1,733 (1,146)
Amortization and other changes in operating lease right-of-use assets 4,067 3,788
Gain on free shares (18) (48)
Stock-based compensation 17,007 12,384
Net changes in operating assets and liabilities:    
Interest receivable 228 148
Accounts receivable (1,658) 31,291
Prepaid expenses and other assets (4,441) (7,763)
Accounts payable and other accrued liabilities (3,204) 1,559
Accrued compensation and employee benefits (3,253) (248)
Deferred revenues (41,481) 178,890
Long-term portion of lease liabilities (2,102) (1,797)
Other non-current liabilities 998 345
Net cash (used in) provided by operating activities (121,117) 141,103
Investing Activities:    
Purchases of marketable securities (180,049) (43,580)
Maturities of marketable securities 323,099 151,839
Sales of marketable securities 6,870 0
Purchases of property and equipment (15,213) (6,694)
Purchase of additional shares of Sangamo France (119) (237)
Net cash provided by investing activities 134,588 101,328
Financing Activities:    
Proceeds from at-the-market offering, net of offering expenses 22,223 0
Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs 0 142,526
Taxes paid related to net share settlement of equity awards (2,725) (455)
Proceeds from exercise of stock options and restricted stock units 3,702 1,307
Proceeds from issuance of common stock under employee stock purchase plan 2,054 1,187
Net cash provided by financing activities 25,254 144,565
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (176) 19
Net increase in cash, cash equivalents, and restricted cash 38,549 387,015
Cash, cash equivalents, and restricted cash, beginning of period 132,829 81,928
Cash, cash equivalents, and restricted cash, end of period 171,378 468,943
Supplemental cash flow disclosures:    
Property and equipment included in unpaid liabilities 2,267 1,977
Right-of-use assets obtained in exchange for lease obligations 1,364 0
Buy-out of non-controlling interest $ 943 $ 0